Clinical Trial Update: A Study of SGN-STNV in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Seagen's Phase 1 study of SGN-STNV in advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• SGN-STNV

Snippet

Sponsor: Seagen Inc. | Conditions: Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms | Phase 1 | Status: TERMINATED